FDA, EMA and Infarmed GMP Guidance and Warning Letters

Official GMP regulatory sample refreshed 19 November 2026: 416 records covering FDA warning letters and guidance, EMA GMP/GDP guidance, EudraLex Volume 4 references, Infarmed…

Last published
Refresh
On-demand
Current documents
416
Licence
Free sampleCC BY 4.0Fork and collectCommercial
Sample
View on GitHub
ShareLinkedInX
# dataIllustrated from this pipeline
  1. paulh

    @Jason build this dataset: gMP guidance and warning letters from FDA, EMA, EudraLex and Infarmed, with document dates, source links and change-comparison fields. The published dataset contains 416 document records. Refreshed on demand.

  2. JasonApp

    On it. Reading europa.euinfarmed.ptfda.gov.

  3. JasonApp

    416 documents, 27 columns in this dataset.

416 documents, refreshed on demand

Sample · 50 rows

You’re viewing a sample of this dataset.

Row#
Open row
1Infarmed2026-11-19First observation of this documentNew—843e736f04c01e13064d92fb00eda3246a9e59cbea4c4289ffa768c79232d2fbSHA-256 of complete PDF bytes2026-11-13Circular issue dateInfarmed:104/CD/550.20.001:2026infarmed.pt/documents/15786/12277905/Limeciclina+Atral+408+mg+Capsula%C2%A0%C2%A0+Levantamento+de+Suspensao+da+AIM/81133d51-5876-662a-b0ef-493eb21cda46?version=1.0Circular: restriction liftedInfarmed—infarmed.pt/web/infarmed/circularesLimeciclina Atral 408 mg Capsula   Levantamento de Suspensao da AIM2026-11-181.0Publication date is the official index posting date; date is the circular issue date.infarmed.pt/documents/15786/12277905/Limeciclina+Atral+408+mg+Capsula%C2%A0%C2%A0+Levantamento+de+Suspensao+da+AIM/81133d51-5876-662a-b0ef-493eb21cda46"Limeciclina Atral 408 mg Cápsula - Levantamento de Suspensão da AIM"Limeciclina Atral 408 mg Capsula Levantamento de Suspensao da AIMinfarmed.pt/documents/15786/12277905/Limeciclina+Atral+408+mg+Capsula%C2%A0%C2%A0+Levantamento+de+Suspensao+da+AIM/81133d51-5876-662a-b0ef-493eb21cda46?version=1.0falseView row
2FDA2026-11-19First observation of this documentNewNatural Essentials, Inc.d22492342afddfbc8e0e0a6ff3ab6287f7ea70d3133f8cd2d37e88a90ca9bb3dSHA-256 of complete normalized document text, excluding website navigation and footer2026-11-10Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026—Warning letterCenter for Drug Evaluation and Research (CDER)2026-11-17fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated/OTC2026-11-17——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026CGMP/Finished Pharmaceuticals/Adulterated/OTCNatural Essentials, Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/natural-essentials-inc-738543-11102026falseView row
3FDA2026-11-19First observation of this documentNewUmicore Argentina S.A.be7ed044ef54dfaab2e685c70c2c2d1d55d3cb684572d227ce45c34c8c9d6fd1SHA-256 of complete normalized document text, excluding website navigation and footer2026-11-06Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umicore-argentina-sa-736869-11062026—Warning letterCenter for Drug Evaluation and Research (CDER)2026-11-17fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Active Pharmaceutical Ingredient (API)/Adulterated2026-11-17——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umicore-argentina-sa-736869-11062026CGMP/Active Pharmaceutical Ingredient (API)/AdulteratedUmicore Argentina S.A. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umicore-argentina-sa-736869-11062026falseView row
4FDA2026-11-19First observation of this documentNewShenzhen Benliju Biotech Co., Ltd.af0def15b7700768792e835078342368d6c55d2cc4eaf8fec625e75d071d0bb1SHA-256 of complete normalized document text, excluding website navigation and footer2026-11-06Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shenzhen-benliju-biotech-co-ltd-738522-11062026—Warning letterCenter for Drug Evaluation and Research (CDER)2026-11-17fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersRequest for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC2026-11-17——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shenzhen-benliju-biotech-co-ltd-738522-11062026Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTCShenzhen Benliju Biotech Co., Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/shenzhen-benliju-biotech-co-ltd-738522-11062026falseView row
5FDA2026-11-19First observation of this documentNewNanjing Hanxin Pharmaceutical Technology Co. Ltd.4a47f6fe5763d608d3663b83ab2ae19e7cec60d396330f295b925619d9bcc398SHA-256 of complete normalized document text, excluding website navigation and footer2026-11-03Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026—Warning letterCenter for Drug Evaluation and Research (CDER)2026-11-10fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersRequest for Records/CGMP/API/Adulterated2026-11-10——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026Request for Records/CGMP/API/AdulteratedNanjing Hanxin Pharmaceutical Technology Co. Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026falseView row
6FDA2026-11-19First observation of this documentNewUSV Private Limited9b7cbe7a859f3d2104429fcf896257494f4f3542f89efbf671ef8e0fa7bd3886SHA-256 of complete normalized document text, excluding website navigation and footer2026-11-02Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usv-private-limited-735938-11022026—Warning letterCenter for Drug Evaluation and Research (CDER)2026-11-10fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-11-10——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usv-private-limited-735938-11022026CGMP/Finished Pharmaceuticals/AdulteratedUSV Private Limited - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usv-private-limited-735938-11022026falseView row
7FDA2026-11-19First observation of this documentNewLGM Pharma Solutions, LLC14d8f50864a15dd411719912bf93b7926ed768cf176dac5648a9b20602d8ccb1SHA-256 of complete normalized document text, excluding website navigation and footer2026-11-02Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lgm-pharma-solutions-llc-736085-11022026—Warning letterCenter for Drug Evaluation and Research (CDER)2026-11-17fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-11-17——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lgm-pharma-solutions-llc-736085-11022026CGMP/Finished Pharmaceuticals/AdulteratedLGM Pharma Solutions, LLC - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lgm-pharma-solutions-llc-736085-11022026falseView row
8FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNew—336760c2b75c7e9d533e7287dcabe87c17d0991431d57d7e0edc165d05ee2793SHA-256 of complete PDF bytes2026-11-02Guidance issue datefda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-productsfda.gov/media/196183/downloadGuidance (final)2026-11-09Center for Biologics Evaluation and Research2026-11-02fda.gov/regulatory-information/search-fda-guidance-documentsGene Therapy2026-11-02——fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-productsFinal guidance; Gene TherapyGuidance for Industry: Potency Assurance for Cellular and Gene Therapy Productsfda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-productsfalseView row
9FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewConroe Welding Supply, Inc.4ecc729857b41ff664865433d884c2ea072368ebbf99031296e3b7d1cf9ad594SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-29Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/conroe-welding-supply-inc-731507-10292026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-11-03fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Medical Gases/Adulterated2026-11-03——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/conroe-welding-supply-inc-731507-10292026CGMP/Medical Gases/AdulteratedConroe Welding Supply, Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/conroe-welding-supply-inc-731507-10292026falseView row
10FDA2026-11-19First observation of this documentNewChongqing Qiancan Technology Co., Ltd.0d66f22f0e6c01c926a88cef7a523db194c547033a5ec24ff832372ac74d8cecSHA-256 of complete normalized document text, excluding website navigation and footer2026-10-29Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chongqing-qiancan-technology-co-ltd-736416-10292026—Warning letterCenter for Drug Evaluation and Research (CDER)2026-11-10fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Active Pharmaceutical Ingredient (API)/Adulterated2026-11-10——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chongqing-qiancan-technology-co-ltd-736416-10292026CGMP/Active Pharmaceutical Ingredient (API)/AdulteratedChongqing Qiancan Technology Co., Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/chongqing-qiancan-technology-co-ltd-736416-10292026falseView row
11FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewPritam International Private Limited9e9cdb3849dc53058b67ec8ad4f5bfea6755550494e4a3c3b1388d18d8accdebSHA-256 of complete normalized document text, excluding website navigation and footer2026-10-27Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-11-03fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-11-03——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026CGMP/Finished Pharmaceuticals/AdulteratedPritam International Private Limited - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pritam-international-private-limited-738079-10272026falseView row
12FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewGuangzhou Jiugong Research And Development Biotechnology Co., Ltd.9b99374ca254dd2a0192c2fd7fdc4d51dda59e403196f2b65a5d2474747d872aSHA-256 of complete normalized document text, excluding website navigation and footer2026-10-27Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-11-03fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated/OTC2026-11-03——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026CGMP/Finished Pharmaceuticals/Adulterated/OTCGuangzhou Jiugong Research And Development Biotechnology Co., Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-10272026falseView row
13Infarmed2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNew—701b016c2a1cb2cb3b774a10565309be0d93c2c74aafdb7f3d7e44c162914ff7SHA-256 of complete PDF bytes2026-10-26Circular issue dateInfarmed:097/CD/550.20.001:2026infarmed.pt/documents/15786/12277901/Recolha+do+medicamento+Besilato+de+Atrac%C3%BArio+Basi%2C+10+mg+ml%2C+Solu%C3%A7%C3%A3o+injet%C3%A1vel+-+lote+n.%C2%BA+P0092%2C+validade+01+2027/54c59033-abcb-beb4-a2b8-cfa5054e32cb?version=1.0Recall circular2026-11-09Infarmed—infarmed.pt/web/infarmed/circularesRecolha do medicamento Besilato de Atracúrio Basi, 10 mg ml, Solução injetável - lote n.º P0092, validade 01 20272026-11-041.0Publication date is the official index posting date; date is the circular issue date.infarmed.pt/documents/15786/12277901/Recolha+do+medicamento+Besilato+de+Atrac%C3%BArio+Basi%2C+10+mg+ml%2C+Solu%C3%A7%C3%A3o+injet%C3%A1vel+-+lote+n.%C2%BA+P0092%2C+validade+01+2027/54c59033-abcb-beb4-a2b8-cfa5054e32cbpor ter sido detetado potencial contaminação e contaminação cruzada.Recolha do medicamento Besilato de Atracúrio Basi, 10 mg ml, Solução injetável - lote n.º P0092, validade 01 2027infarmed.pt/documents/15786/12277901/Recolha+do+medicamento+Besilato+de+Atrac%C3%BArio+Basi%2C+10+mg+ml%2C+Solu%C3%A7%C3%A3o+injet%C3%A1vel+-+lote+n.%C2%BA+P0092%2C+validade+01+2027/54c59033-abcb-beb4-a2b8-cfa5054e32cb?version=1.0falseView row
14FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewGuangdong Bangze Medicine Co., Ltd.25acc1a90178ad0b4406456826cb93791bc3bd126c58a2585f706f21a14bff56SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-26Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangdong-bangze-medicine-co-ltd-734509-10262026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-11-03fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated/OTC2026-11-03——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangdong-bangze-medicine-co-ltd-734509-10262026CGMP/Finished Pharmaceuticals/Adulterated/OTCGuangdong Bangze Medicine Co., Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/guangdong-bangze-medicine-co-ltd-734509-10262026falseView row
15FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewTSP Solutions Pte. Ltd.f83dc2813a5dc790bfd721e38f102bab2f75e66c26666f6ec344cbaffea38cc2SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-22Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tsp-solutions-pte-ltd-735071-10222026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-27fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersRequest for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTC2026-10-27——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tsp-solutions-pte-ltd-735071-10222026Request for Records/CGMP/Finished Pharmaceuticals/Adulterated/OTCTSP Solutions Pte. Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tsp-solutions-pte-ltd-735071-10222026falseView row
16FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewSanrace Biotechnology Co., Ltd.70b35f2a5df9dadd55362c72293475acdf70133eb034d2cfcad117d6836320e3SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-22Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanrace-biotechnology-co-ltd-737549-10222026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-27fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-27——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanrace-biotechnology-co-ltd-737549-10222026CGMP/Finished Pharmaceuticals/AdulteratedSanrace Biotechnology Co., Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanrace-biotechnology-co-ltd-737549-10222026falseView row
17FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewNorthland Nuclear Medicine, LLCe81fed15b67a6d7062241bb691916b5aaf6e101034ea62c63e29d59436c986dbSHA-256 of complete normalized document text, excluding website navigation and footer2026-10-22Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/northland-nuclear-medicine-llc-736893-10222026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-27fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-27——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/northland-nuclear-medicine-llc-736893-10222026CGMP/Finished Pharmaceuticals/AdulteratedNorthland Nuclear Medicine, LLC - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/northland-nuclear-medicine-llc-736893-10222026falseView row
18FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewBausch & Lomb Inc. 6e0a2c824803440e26d3d0d8738582945bdc62dc74e5b4d2917476910c63ba87SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-04Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-15fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-09-15——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026CGMP/Finished Pharmaceuticals/AdulteratedBausch & Lomb Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026falseView row
19EMA / EudraGMDP2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewGlukem Biocare Private Limited5c641ff22fe5539a2e9baa1157b2de76bbece01801d70db242ec8529df333ac8SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-16Report issue dateeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188112eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.doGMP non-compliance report2026-11-09Malta Medicines Authority—eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do1.2  Non-sterile products 1.2.1  Non-sterile products (processing operations for the following dosage forms) 1.2.1.17  Other: Manufacture of intermediates (pellets)(en) 1.6  Quality control testing 1.6.2  Microbiological: non-sterility 1.6.3  Chemical/Physical2026-10-16—Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188112The inspection resulted in a critical deficiency related to contamination risk in the Fluid Bed Coating (FBC) equipment due to an observed pool of liquid and residue in a section of the inlet air plenum of a fully cleaned FBC. The flaws were due to common design between FBCs (inclination of plenum not allowing gravity draining) and inadequate cleaning procedure. In addition, there was no detectability of a failure in HEPA filter integrity through real-time monitoring of pressure differential before and after the supply air HEPA filter of the Air Handling Units of the FBCs. There were eleven (11) major findings relating to: Inadequate Master Batch Record instructions and production documentation; Deficient process validation, including insufficient coverage of process, demonstration of its reproducibility and pellet homogeneity; Incomplete cleaning validation; Differential pressure excursions; Deficient warehouse, sampling and dispensing controls; Inadequate vendor qualification; Inadequate identification testing of incoming starting materials, Excipient risk assessments, Out-of-Specification handling, Equipment qualification and Pest control.MT/004NCR/2026 - Glukem Biocare Private Limitedeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188112falseView row
20FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewRohto Pharmaceutical Co., Ltd.73ce1ceb50da453ec2cff67b2bfd194bf1f0eed36ac4c54bbb8085fd030fa510SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-14Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-20fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated/OTC2026-10-20——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated/OTCRohto Pharmaceutical Co., Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026falseView row
21FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNew—ec163d276b071f94604724d9fa362f0b13f7bb266b02eb46526683c87a7a329aSHA-256 of complete PDF bytes2026-10-09Guidance issue datefda.gov/regulatory-information/search-fda-guidance-documents/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-andfda.gov/media/180206/downloadGuidance (final)2026-11-09Center for Drug Evaluation and Research2026-10-13fda.gov/regulatory-information/search-fda-guidance-documentsBiosimilars2026-10-09——fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-andFinal guidance; BiosimilarsPostapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answersfda.gov/regulatory-information/search-fda-guidance-documents/postapproval-manufacturing-changes-biosimilar-and-interchangeable-biosimilar-products-questions-andfalseView row
22EMA / EudraGMDP2026-11-19First observation of this documentNewHet Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting61a5e2c6a1d42787fa249fe907248f53609ac715cd28c07fbb336d6cbe9b0945SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-08Report issue dateeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188001eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.doGMP non-compliance reportHealth And Youth Care Inspectorate—eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do1.1  Sterile products 1.1.1  Aseptically prepared (processing operations for the following dosage forms) 1.1.1.2  Lyophilisates 1.1.1.4  Small volume liquids 1.1.1.6  Other: cell therapy products and gene therapy products(en) 1.2  Non-sterile products 1.2.1  Non-sterile products (processing operations for the following dosage forms) 1.2.1.1  Capsules, hard shell 1.2.1.13  Tablets 1.3  Biological medicinal products (list of product types) 1.3.1  Biological medicinal products (list of product types) 1.3.1.3  Cell therapy products 1.3.1.4  Gene therapy products 1.3.1.5  Biotechnology products 1.5  Packaging 1.5.1  Primary Packaging 1.5.1.1  Capsules, hard shell 1.5.1.13  Tablets 1.5.2  Secondary packaging Clarifying remarks (for public users): Activities restricted to the location Louwesweg 6 in Amsterdam.2026-10-08—Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188001The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human investigational medicines. It concerns sterile production of registered products and ATMPs and non-sterile production of registered products. In addition, the activities of investigational medicinal products are manufacturing of tablets/capsules, and relabeling and repackaging. All of the clinical studies are performed in the Netherlands, except one study is performed in Europe (M22BOL EU CT 2023-505039-11-00). The outcome of the inspection was GMP non-compliant, which is based on one (1) critical deficiency, seven (7) major deficiencies and fourteen (14) other deficiencies. In summary the main inspection findings were as follows: Critical deficiency: 1) The execution of the Out-of-Specification (OOS) process is inadequate. In practice, multiple batches of registered finished products were released even though they did not comply with the specified limits for moisture content or assay. An Advanced Therapy Medicinal Product (ATMP) was released despite a failed sterility test which was performed as an in-process control. In addition, the procedure for OOS is not unambiguous and can lead to batch certification and release without thorough investigation of sufficient justification. Major deficiencies: 1) The control of aseptic practices for both the registered product and the ATMP manufacturing process is insufficient e.g. Annex1 gap assessment and the contamination control strategy are incomplete. Regarding ATMP production multiple aspects are not under control. 2) Aseptic process simulation is inadequate for both the registered product and the ATMP process, including the additional media fill. 3) The design, investigation and trending of microbiological test results are insufficient for example multiple microbial exceedances on the hands of the operators in class A handling the ATMP product. 4) Operator behaviour in the cleanroom and gowning procedures for Grade B areas are inadequate. 5) The Pharmaceutical Quality System (PQS) is insufficient. This is shown by deficiencies identified in the management of deviations, CAPAs, changes, complaints, self-inspections, and the Product Quality Reviews (PQRs) that were assessed. 6) The approach to Computerized System Validation (CSV) and data integrity is inadequate. 7) Good Documentation Practices (GDocP) are not sufficiently adhered to, as demonstrated for example by the backlog of revisions for multiple documents. In conclusion: the impact of the GMP non-compliance on registered products, ATMPs and most of the investigational medicinal products is exclusively national, except for one clinical study (EU CT 2023-505039-11-00)(see paragraph: suspension of clinical trials).NL/H 26/2008484B - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichtingeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=188001falseView row
23EMA / EudraGMDP2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewHet Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting7f05863b911dbbce73e2a3f67638c5ffb5285c28e7e439a601e4d32649d7c719SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-07Report issue dateeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187964eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.doGMP non-compliance report2026-11-09Health And Youth Care Inspectorate—eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do1.1  Sterile products 1.1.1  Aseptically prepared (processing operations for the following dosage forms) 1.1.1.6  Other: cell therapy products and gene therapy products(en) 1.1.3  Batch certification 1.2  Non-sterile products 1.2.2  Batch certification 1.3  Biological medicinal products (list of product types) 1.3.1  Biological medicinal products (list of product types) 1.3.1.3  Cell therapy products Special Requirements: 3  Live Cells 1.3.1.4  Gene therapy products Special Requirements: 3  Live Cells 1.3.1.5  Biotechnology products Special Requirements: 3  Live Cells 1.3.2  Batch Certification (list of product types) 1.3.2.3  Cell therapy products 1.3.2.4  Gene therapy products 1.3.2.5  Biotechnology products 1.5  Packaging 1.5.2  Secondary packaging 1.6  Quality control testing 1.6.1  Microbiological: sterility 1.6.2  Microbiological: non-sterility 1.6.3  Chemical/Physical 1.6.4  Biological Clarifying remarks (for public users): ad 1.1.3 and 1.2.2: Batch certification of human investigational medicinal products, prepared at location :Louwesweg 6 as well as location Plesmanlaan 121 in Amsterdam is performed at location Plesmanlaan 121 in Amsterdam; ad 1.6.4 concerns endotoxin tests and flowcytometry.2026-10-07—Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187964The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human investigational medicines. It concerns sterile production of registered products and ATMPs and non-sterile production of registered products. In addition, the activities of investigational medicinal products are manufacturing of tablets/capsules, and relabeling and repackaging. All of the clinical studies are performed in the Netherlands, except one study is performed in Europe (M22BOL EU CT 2023-505039-11-00). The outcome of the inspection was GMP non-compliant, which is based on one (1) critical deficiency, seven (7) major deficiencies and fourteen (14) other deficiencies. In summary the main inspection findings were as follows: Critical deficiency: 1) The execution of the Out-of-Specification (OOS) process is inadequate. In practice, multiple batches of registered finished products were released even though they did not comply with the specified limits for moisture content or assay. An Advanced Therapy Medicinal Product (ATMP) was released despite a failed sterility test which was performed as an in-process control. In addition, the procedure for OOS is not unambiguous and can lead to batch certification and release without thorough investigation of sufficient justification. Major deficiencies: 1) The control of aseptic practices for both the registered product and the ATMP manufacturing process is insufficient e.g. Annex1 gap assessment and the contamination control strategy are incomplete. Regarding ATMP production multiple aspects are not under control. 2) Aseptic process simulation is inadequate for both the registered product and the ATMP process, including the additional media fill. 3) The design, investigation and trending of microbiological test results are insufficient for example multiple microbial exceedances on the hands of the operators in class A handling the ATMP product. 4) Operator behaviour in the cleanroom and gowning procedures for Grade B areas are inadequate. 5) The Pharmaceutical Quality System (PQS) is insufficient. This is shown by deficiencies identified in the management of deviations, CAPAs, changes, complaints, self-inspections, and the Product Quality Reviews (PQRs) that were assessed. 6) The approach to Computerized System Validation (CSV) and data integrity is inadequate. 7) Good Documentation Practices (GDocP) are not sufficiently adhered to, as demonstrated for example by the backlog of revisions for multiple documents. In conclusion: the impact of the GMP non-compliance on registered products, ATMPs and most of the investigational medicinal products is exclusively national, except for one clinical study (EU CT 2023-505039-11-00)(see paragraph: suspension of clinical trials).NL/H 26/2008484D - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichtingeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187964falseView row
24EMA / EudraGMDP2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewHet Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting21d12a7e6d07b27146b8d74c7c648cbe1b1c71fc5ad7daedefe5080ac5aa62caSHA-256 of complete normalized document text, excluding website navigation and footer2026-10-07Report issue dateeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187963eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.doGMP non-compliance report2026-11-09Health And Youth Care Inspectorate—eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do1.1  Sterile products 1.1.3  Batch certification 1.2  Non-sterile products 1.2.2  Batch certification 1.6  Quality control testing 1.6.1  Microbiological: sterility 1.6.2  Microbiological: non-sterility 1.6.3  Chemical/Physical 1.6.4  Biological Clarifying remarks (for public users): ad 1.1.3 and 1.2.2: Batch certification of human related products prepared at location Louwesweg 6 in Amsterdam, is performed at location Plesmanlaan 121 in Amsterdam; ad 1.1.3 batch certification (lyophilisates); ad 1.2.2 batch certification (other solods dosage forms); af 1.6.4 concerns endotoxin tests.2026-10-07—Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187963The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human investigational medicines. It concerns sterile production of registered products and ATMPs and non-sterile production of registered products. In addition, the activities of investigational medicinal products are manufacturing of tablets/capsules, and relabeling and repackaging. All of the clinical studies are performed in the Netherlands, except one study is performed in Europe (M22BOL EU CT 2023-505039-11-00). The outcome of the inspection was GMP non-compliant, which is based on one (1) critical deficiency, seven (7) major deficiencies and fourteen (14) other deficiencies. In summary the main inspection findings were as follows: Critical deficiency: 1) The execution of the Out-of-Specification (OOS) process is inadequate. In practice, multiple batches of registered finished products were released even though they did not comply with the specified limits for moisture content or assay. An Advanced Therapy Medicinal Product (ATMP) was released despite a failed sterility test which was performed as an in-process control. In addition, the procedure for OOS is not unambiguous and can lead to batch certification and release without thorough investigation of sufficient justification. Major deficiencies: 1) The control of aseptic practices for both the registered product and the ATMP manufacturing process is insufficient e.g. Annex1 gap assessment and the contamination control strategy are incomplete. Regarding ATMP production multiple aspects are not under control. 2) Aseptic process simulation is inadequate for both the registered product and the ATMP process, including the additional media fill. 3) The design, investigation and trending of microbiological test results are insufficient for example multiple microbial exceedances on the hands of the operators in class A handling the ATMP product. 4) Operator behaviour in the cleanroom and gowning procedures for Grade B areas are inadequate. 5) The Pharmaceutical Quality System (PQS) is insufficient. This is shown by deficiencies identified in the management of deviations, CAPAs, changes, complaints, self-inspections, and the Product Quality Reviews (PQRs) that were assessed. 6) The approach to Computerized System Validation (CSV) and data integrity is inadequate. 7) Good Documentation Practices (GDocP) are not sufficiently adhered to, as demonstrated for example by the backlog of revisions for multiple documents. In conclusion: the impact of the GMP non-compliance on registered products, ATMPs and most of the investigational medicinal products is exclusively national, except for one clinical study (EU CT 2023-505039-11-00)(see paragraph: suspension of clinical trials).NL/H 26/2008484C - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichtingeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187963falseView row
25EMA / EudraGMDP2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewHet Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting0c7884ef52dfa4396f7e7bdbd22121c9526f636133ce213cf734fbbbf38fbb91SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-07Report issue dateeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187962eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.doGMP non-compliance report2026-11-09Health And Youth Care Inspectorate—eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do1.1  Sterile products 1.1.1  Aseptically prepared (processing operations for the following dosage forms) 1.1.1.2  Lyophilisates 1.2  Non-sterile products 1.2.1  Non-sterile products (processing operations for the following dosage forms) 1.2.1.8  Other solid dosage forms 1.5  Packaging 1.5.1  Primary Packaging 1.5.1.8  Other solid dosage forms 1.5.2  Secondary packaging Clarifying remarks (for public users): Activities restricted to the location Louwesweg 6 in Amsterdam.2026-10-07—Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187962The GMP inspection has been performed on February 10–12, 2026 and April 22-23, 2026. This manufacturer, a hospital pharmacy, is producing multiple type of products: medicinal products for human use with a marketing authorization, advanced therapy medicinal products (ATMPs, investigational) and human investigational medicines. It concerns sterile production of registered products and ATMPs and non-sterile production of registered products. In addition, the activities of investigational medicinal products are manufacturing of tablets/capsules, and relabeling and repackaging. All of the clinical studies are performed in the Netherlands, except one study is performed in Europe (M22BOL EU CT 2023-505039-11-00). The outcome of the inspection was GMP non-compliant, which is based on one (1) critical deficiency, seven (7) major deficiencies and fourteen (14) other deficiencies. In summary the main inspection findings were as follows: Critical deficiency: 1) The execution of the Out-of-Specification (OOS) process is inadequate. In practice, multiple batches of registered finished products were released even though they did not comply with the specified limits for moisture content or assay. An Advanced Therapy Medicinal Product (ATMP) was released despite a failed sterility test which was performed as an in-process control. In addition, the procedure for OOS is not unambiguous and can lead to batch certification and release without thorough investigation of sufficient justification. Major deficiencies: 1) The control of aseptic practices for both the registered product and the ATMP manufacturing process is insufficient e.g. Annex1 gap assessment and the contamination control strategy are incomplete. Regarding ATMP production multiple aspects are not under control. 2) Aseptic process simulation is inadequate for both the registered product and the ATMP process, including the additional media fill. 3) The design, investigation and trending of microbiological test results are insufficient for example multiple microbial exceedances on the hands of the operators in class A handling the ATMP product. 4) Operator behaviour in the cleanroom and gowning procedures for Grade B areas are inadequate. 5) The Pharmaceutical Quality System (PQS) is insufficient. This is shown by deficiencies identified in the management of deviations, CAPAs, changes, complaints, self-inspections, and the Product Quality Reviews (PQRs) that were assessed. 6) The approach to Computerized System Validation (CSV) and data integrity is inadequate. 7) Good Documentation Practices (GDocP) are not sufficiently adhered to, as demonstrated for example by the backlog of revisions for multiple documents. In conclusion: the impact of the GMP non-compliance on registered products, ATMPs and most of the investigational medicinal products is exclusively national, except for one clinical study (EU CT 2023-505039-11-00)(see paragraph: suspension of clinical trials).NL/H 26/2008484A - Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichtingeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187962falseView row
26FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewEurofins SF Analytical Laboratories, Inc.576b4707da31402ebd35a1fdee9b423f307a128c6434bbb534ed82be4be4f0a6SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-06Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-13fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-13——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026CGMP/Finished Pharmaceuticals/AdulteratedEurofins SF Analytical Laboratories, Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eurofins-sf-analytical-laboratories-inc-736056-10062026falseView row
27FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewSilgan Dispensing Systems8ea2906f44040f50280456f74d265ef8d92a30c3dd4e18ad46f0e3b15093b8faSHA-256 of complete normalized document text, excluding website navigation and footer2026-10-05Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/silgan-dispensing-systems-734538-10052026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-13fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/OTC2026-10-13——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/silgan-dispensing-systems-734538-10052026CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug/OTCSilgan Dispensing Systems - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/silgan-dispensing-systems-734538-10052026falseView row
28FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewHanlim Pharm Co., Ltd.3fb0d9b6514ad99c40ad712eb45d2bb052621d72ec1dae9724420771b108d513SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-02Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hanlim-pharm-co-ltd-734782-10022026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-13fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-13——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hanlim-pharm-co-ltd-734782-10022026CGMP/Finished Pharmaceuticals/AdulteratedHanlim Pharm Co., Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hanlim-pharm-co-ltd-734782-10022026falseView row
29FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewZhejiang Gaorong Cosmetic Co., Ltd.d5e34296fc9dbac5fcc6e439a663a2127fae21592079332254ea0b227cb48387SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-01Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-gaorong-cosmetic-co-ltd-732511-10012026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-20fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-20——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-gaorong-cosmetic-co-ltd-732511-10012026CGMP/Finished Pharmaceuticals/AdulteratedZhejiang Gaorong Cosmetic Co., Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zhejiang-gaorong-cosmetic-co-ltd-732511-10012026falseView row
30FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewSignature Formulations LLC31172b18651386d85ce560295d8b7a303f640ea509a172699824c9df962a8528SHA-256 of complete normalized document text, excluding website navigation and footer2026-10-01Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signature-formulations-llc-737964-10012026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-20fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-20——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signature-formulations-llc-737964-10012026CGMP/Finished Pharmaceuticals/AdulteratedSignature Formulations LLC - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/signature-formulations-llc-737964-10012026falseView row
31FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewBaxter International Inc.3d8ba70c46fdf22b5211ab4a7aff10be676bfb613584beb6a37a033a2b8e8187SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-29Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-20fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-20——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026CGMP/Finished Pharmaceuticals/AdulteratedBaxter International Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026falseView row
32FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewSnugZ USA, Inc. af261fc4a26df5dbc6c04d9dc60c493223acb0aaeec6963d66829c75a443ecd4SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-28Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-20fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-20——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026CGMP/Finished Pharmaceuticals/AdulteratedSnugZ USA, Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/snugz-usa-inc-735284-09282026falseView row
33EMA / EudraGMDP2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewOcb Pharmaceutical S.R.L.c40897cf2bcd5215e2f245a71be0b99b155d07c2a86c55c007f51c54a816a263SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-28Report issue dateeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187807eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.doGMP non-compliance report2026-11-09Spanish Agency Of Medicines And Medical Devices—eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do1.4  Other products or manufacturing activity 1.4.1  Manufacture of 1.4.1.3  Other: Manufacturing of active substances(en) Manufacture of active substance. Names of substances subject to non-compliant: BISMUTH CITRATE(en) [2187WR]BISMUTH SUBCITRATE COLLOIDAL(en) [90105A]BISMUTH SUBGALLATE(en) [90773A]BISMUTH SUBNITRATE(en) [136BP]BISMUTH SUBSALICYLATE(en) [9087A]SODIUM AND BISMUTH TARTRATE(en) [503TFB]BISMUTH TRIBROMOPHENATE(en) [503OX]BISMUTH OXIDE(en) [503BSC]BISMUTH SUBCARBONATE(en) 3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES Active Substance:BISMUTH CITRATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1  Physical processing steps: drying, milling 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBCITRATE COLLOIDAL 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2  Manufacture of crude active substance 3.5 General Finishing Steps 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBGALLATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1  Physical processing steps: drying, milling or micronisation 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBNITRATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1  Physical processing steps: drying, milling 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBSALICYLATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1  Physical processing steps: drying, milling or micronisation 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:SODIUM AND BISMUTH TARTRATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2  Manufacture of crude active substance 3.5 General Finishing Steps 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:BISMUTH TRIBROMOPHENATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1  Physical processing steps: drying, milling 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:BISMUTH OXIDE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1  Physical processing steps: drying, milling 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:BISMUTH SUBCARBONATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: Separation of the active substance of mother waters by centrifugation. Washing with deionized water 3.5 General Finishing Steps 3.5.1  Physical processing steps: drying, milling 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing2026-09-28—Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187807During the inspection, a total of nine (9) deficiencies were identified, one (1) of them were classified as critical and eight (8) as major. The deficiencies identified demonstrate significant weakness in the pharmaceutical quality system implemented at the site and raise serious concerns regarding the reliability of manufacturing, storage, documentation, cross contamination control, traceability and quality assurance oversight activities. The critical deficiency related to the repackaging, relabelling and distribution of bismuth subsalicylate originating from a Chinese manufacturing operating outside the EU GMP framework. The inspection demonstrated that OCB PHARMACEUTICAL, S.R.L. assigned new batch numbers, issued certificates of analysis containing analytical results copied from supplier documentation, removed or replaced original labels and distributed the material to pharmaceutical costumers without adequately preserving the identity of the original manufacturer and the traceability of the supply chain. These practices gave the material the appearance of being associated with OCB PHARMACEUTICAL, S.R.L. manufacturing activities, not complying with GMP Part II requirements concerning the integrity and traceability of the supply chain. Major deficiencies were identified in the effectiveness of the deviation, investigation, CAPA and risk management system; data integrity controls, personnel qualification and training; material management and traceability; contamination and cross-contamination control measures; maintenance and cleaning of facilities and equipment; documentation practices; and quality system governance. The combination of these deficiencies indicates that the quality management system is not capable of consistently ensuring the manufacture, storage and distribution of active substances in compliance with GMP Part II requirements.Particular concerns were identified regarding the design, maintenance, qualification and operation of HVAC systems and differential pressure controls, recurring environmental monitoring excursions, deficiencies in cleaning practices, uncontrolled access between classified and technical areas, inadequate investigation of contamination events and the lack of effective reassessment of cross-contamination risks following multiple significant quality incidents. These deficiencies may have compromised the effectiveness of controls intended to prevent contamination and cross-contamination of active substances manufactured at the site. In addition, deficiencies in governance and management oversight were observed. The inspection findings demonstrate that quality-related decisions were not always supported by adequate quality risk management principles and the quality unit did not exercise sufficient authority to ensure that manufacturing activities were restricted, suspended or adequately controlled when significant quality concerns were identified.NCF-II/NC2026/01/CAT - Ocb Pharmaceutical S.R.L.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187807falseView row
34FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewJiangmen Shuizirun Sanitary Articles Co., Ltd. 64f65f7a58759f493878cf8643093fcdd73c4b675271af17ed42ae98155e2303SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-23Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangmen-shuizirun-sanitary-articles-co-ltd-722974-09232026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-13fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated/OTC2026-10-13——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangmen-shuizirun-sanitary-articles-co-ltd-722974-09232026CGMP/Finished Pharmaceuticals/Adulterated/OTCJiangmen Shuizirun Sanitary Articles Co., Ltd. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jiangmen-shuizirun-sanitary-articles-co-ltd-722974-09232026falseView row
35FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNew Fresenius Kabi USA LLC2e5048b6b3ca078fae32ff37e632d2dd23b1762816d94f86fd7999cc354e72ecSHA-256 of complete normalized document text, excluding website navigation and footer2026-09-22Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-kabi-usa-llc-733107-09222026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-29fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-09-29——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-kabi-usa-llc-733107-09222026CGMP/Finished Pharmaceuticals/AdulteratedFresenius Kabi USA LLC - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-kabi-usa-llc-733107-09222026falseView row
36FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewBabikian Healthcare Products CJSCe079bcb87445474e6d2ec3e358c0cc8c2f25e57dfc324710efa7d7348bb77d43SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-21Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-29fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-09-29——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026CGMP/Finished Pharmaceuticals/AdulteratedBabikian Healthcare Products CJSC - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/babikian-healthcare-products-cjsc-730513-09212026falseView row
37EMA / EudraGMDP2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewXi'an Guokang Ruijin Pharmaceutical Co. Ltd.61e283eacfb05bf69ca1014ed74712fbd5d6f1a39df14990423ef1abb1ce6d6dSHA-256 of complete normalized document text, excluding website navigation and footer2026-09-21Report issue dateeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187670eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.doGMP non-compliance report2026-11-09Finnish Medicines Agency—eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do1.4  Other products or manufacturing activity 1.4.1  Manufacture of 1.4.1.3  Other: active substance(en) Manufacture of active substance. Names of substances subject to non-compliant: DEXAMETHASONE SODIUM PHOSPHATE(en) BETAMETHASONE(en) DEXAMETHASONE(en) 3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES Active Substance:DEXAMETHASONE SODIUM PHOSPHATE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture of active substance intermediates 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: crystallization 3.5 General Finishing Steps 3.5.1  Physical processing steps: milling 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:BETAMETHASONE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture of active substance intermediates 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: crystallization 3.5 General Finishing Steps 3.5.1  Physical processing steps: milling 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Active Substance:DEXAMETHASONE 3.1 Manufacture of Active Substance by Chemical Synthesis 3.1.1  Manufacture of active substance intermediates 3.1.2  Manufacture of crude active substance 3.1.3  Salt formation / Purification steps: crystallization 3.5 General Finishing Steps 3.5.1  Physical processing steps: milling 3.5.2  Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3  Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) 3.6 Quality Control Testing 3.6.1  Physical / Chemical testing 3.6.2  Microbiological testing excluding sterility testing Clarifying remarks (for public users): Dexamethasone covers crystalline forms A and B2026-09-21—Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187670The inspection team identified 18 deficiencies (grouped) against EU GMP, of which 11 were classified as Major. The major deficiencies were related to: Inadequacy of Quality Assurance oversight and Quality management system Inadequate design, poor maintenance/cleaning, lack of contamination control in intermediates manufacturing facilities Solvent recovery, lack of traceability and risk of cross-contamination Risk of supplying non-GMP APIs for production of medicinal products for human or animal use Change control Data integrity of documentation and records Traceability and control of material throughout the manufacturing process Cleaning and process validation Material management Insufficient control of analytical methods Incomplete understanding and incorrect application of fundamental GMP principlesFIMEA/2026/003795 - Xi'an Guokang Ruijin Pharmaceutical Co. Ltd.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187670falseView row
38FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewEmpower Clinic Services, LLC dba Empower Pharmacy1a6a9e08e65bebfd99712884f3e6fe1bc24d4f2aa1cb83d6c7517fbdee96140cSHA-256 of complete normalized document text, excluding website navigation and footer2026-09-18Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-22fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug2026-09-22——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New DrugEmpower Clinic Services, LLC dba Empower Pharmacy - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026falseView row
39FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewCuria New York, Inc. f6f9277a66dbd51c6968387a96ebdd01887a1a5a002f99f11865e38a1a5f2105SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-18Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curia-new-york-inc-728790-09182026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-29fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Active Pharmaceutical Ingredient (API)/Adulterated2026-09-29——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curia-new-york-inc-728790-09182026CGMP/Active Pharmaceutical Ingredient (API)/AdulteratedCuria New York, Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curia-new-york-inc-728790-09182026falseView row
40FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewBentley Laboratories LLC89ba8bef67a1798f9e446ba49faab0c97eea62f64c5e08d773abf5347eab9b74SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-17Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bentley-laboratories-llc-732028-09172026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-29fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated2026-09-29——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bentley-laboratories-llc-732028-09172026CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/AdulteratedBentley Laboratories LLC - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bentley-laboratories-llc-732028-09172026falseView row
41FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNew—bd4f2c82ea379c463e3cd034535699654d000191a302bf2723e695c57186ad14SHA-256 of complete PDF bytes2026-09-16Guidance issue datefda.gov/regulatory-information/search-fda-guidance-documents/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-bloodfda.gov/media/182751/downloadGuidance (final)2026-11-09Center for Biologics Evaluation and Research2026-09-17fda.gov/regulatory-information/search-fda-guidance-documentsBlood, Blood Products2026-09-16——fda.gov/regulatory-information/search-fda-guidance-documents/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-bloodFinal guidance; Blood, Blood ProductsRecommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Methodfda.gov/regulatory-information/search-fda-guidance-documents/recommendations-development-blood-collection-processing-and-storage-systems-manufacture-bloodfalseView row
42FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewSCA Pharmaceuticals, LLCe4bebf91f0bb4853fd726bbcb2727a4744c9957e7df5d6c5a96ceb216f129076SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-14Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sca-pharmaceuticals-llc-724202-09142026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-13fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-13——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sca-pharmaceuticals-llc-724202-09142026CGMP/Finished Pharmaceuticals/AdulteratedSCA Pharmaceuticals, LLC - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sca-pharmaceuticals-llc-724202-09142026falseView row
43FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewkdc/one Chatsworth, Inc.dc3f8cee08bb2e8e1435aec5c4c92780a72543e4ba7d5a831a57be54685f796aSHA-256 of complete normalized document text, excluding website navigation and footer2026-09-08Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kdcone-chatsworth-inc-733205-09082026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-22fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-09-22——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kdcone-chatsworth-inc-733205-09082026CGMP/Finished Pharmaceuticals/Adulteratedkdc/one Chatsworth, Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kdcone-chatsworth-inc-733205-09082026falseView row
44EMA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNew—4130b578aa945eb72531eb6986978681100e28a34dfda5f8e4ccc3bf57cd851eSHA-256 of complete PDF bytes2026-09-07Last updated date where stated; otherwise first publicationema.europa.eu/en/documents/regulatory-procedural-guideline/co-ordinating-good-manufacturing-practice-gmp-inspections-centrally-authorised-products_en.pdfema.europa.eu/en/documents/regulatory-procedural-guideline/co-ordinating-good-manufacturing-practice-gmp-inspections-centrally-authorised-products_en.pdfGMP/GDP guidance2026-11-09EMA2026-09-07ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/compilation-union-procedures-inspections-exchange-informationGMP / pharmaceutical manufacturing2024-08-013Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products Legal effective date: 10/09/2026 English (EN) (173.93 KB - PDF) First published: 01/08/2024 Last updated: 07/09/2026 Viewema.europa.eu/en/documents/regulatory-procedural-guideline/co-ordinating-good-manufacturing-practice-gmp-inspections-centrally-authorised-products_en.pdfGuidance on Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised productsCo-ordinating good manufacturing practice (GMP) inspections for centrally authorised productsema.europa.eu/en/documents/regulatory-procedural-guideline/co-ordinating-good-manufacturing-practice-gmp-inspections-centrally-authorised-products_en.pdffalseView row
45Infarmed2026-11-19Document unavailable; no content hash or change determination possibleUnknown———2026-09-04Circular issue date stated on official document pageInfarmed:087/CD/550.20.001:2026infarmed.pt/documents/15786/12277909/Suspens%C3%A3o+de+fabrico+e+recolha+de+solu%C3%A7%C3%B5es+est%C3%A9reis+do+fabricante+Sterisets+Manufacturing%2C+SA/89087f2b-4905-d01f-207d-2fc6162b2214?version=1.0Recall circular2026-11-09Infarmed2026-11-03infarmed.pt/web/infarmed/circularesSuspensão de fabrico e recolha de soluções estéreis do fabricante Sterisets Manufacturing, SA2026-11-031.0Official document page metadata verified; the attachment could not be downloaded. Document content and changes are unknown.infarmed.pt/web/infarmed/institucional/documentacao_e_informacao/informacao-tematica?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&_101_struts_action=%2Fasset_publisher%2Fview_content&_101_assetEntryId=13774111&_101_type=documentManufacturing suspension and recall of sterile solutions, as stated by the official notice title. Full document unavailable.Suspensão de fabrico e recolha de soluções estéreis do fabricante Sterisets Manufacturing, SAinfarmed.pt/documents/15786/12277909/Suspens%C3%A3o+de+fabrico+e+recolha+de+solu%C3%A7%C3%B5es+est%C3%A9reis+do+fabricante+Sterisets+Manufacturing%2C+SA/89087f2b-4905-d01f-207d-2fc6162b2214?version=1.0trueView row
46FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewTCI Co., Ltd BioCosme PABP BRANCHc48d2e5458ef30bbb9fea43e1035463c570bbceb885d5b6560601c840e756136SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-02Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tci-co-ltd-biocosme-pabp-branch-736888-09022026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-10-06fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-10-06——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tci-co-ltd-biocosme-pabp-branch-736888-09022026CGMP/Finished Pharmaceuticals/AdulteratedTCI Co., Ltd BioCosme PABP BRANCH - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tci-co-ltd-biocosme-pabp-branch-736888-09022026falseView row
47FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewHappy Farm Botanicals, Inc.24b112821657bc796aba99b576693538a393e4ff054f1edfd719c163db8c21a1SHA-256 of complete normalized document text, excluding website navigation and footer2026-09-01Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happy-farm-botanicals-inc-731926-09012026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-08fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-09-08——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happy-farm-botanicals-inc-731926-09012026CGMP/Finished Pharmaceuticals/AdulteratedHappy Farm Botanicals, Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happy-farm-botanicals-inc-731926-09012026falseView row
48FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewJabil Inc.ae8530911c10ca8c649144d06061e5470d0a3f9c42a781579b2622a82a702486SHA-256 of complete normalized document text, excluding website navigation and footer2026-08-27Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-01fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-09-01——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026CGMP/Finished Pharmaceuticals/AdulteratedJabil Inc. - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/jabil-inc-731037-08272026falseView row
49FDA2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewFresenius Medical Care AG & Co. KGaA8320a869feec025ddf610f0d4236fccac464f08c195a4e0161764b5abca0983fSHA-256 of complete normalized document text, excluding website navigation and footer2026-08-25Letter issue datefda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-medical-care-ag-co-kgaa-730319-08252026—Warning letter2026-11-09Center for Drug Evaluation and Research (CDER)2026-09-01fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-lettersCGMP/Finished Pharmaceuticals/Adulterated2026-09-01——fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-medical-care-ag-co-kgaa-730319-08252026CGMP/Finished Pharmaceuticals/AdulteratedFresenius Medical Care AG & Co. KGaA - GMP warning letterfda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fresenius-medical-care-ag-co-kgaa-730319-08252026falseView row
50EMA / EudraGMDP2026-11-19Initial content-hash baseline; legacy sample has no comparable hashNewAculife Healthcare Private Limitedb8557b3becb5e1a77744504456c09c14b15812ec07db8616b15fb1788f462cdfSHA-256 of complete normalized document text, excluding website navigation and footer2026-08-24Report issue dateeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187173eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.doGMP non-compliance report2026-11-09Malta Medicines Authority—eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do1.1  Sterile products 1.1.1  Aseptically prepared (processing operations for the following dosage forms) 1.1.1.4  Small volume liquids 1.1.2  Terminally Sterilised (processing operations for the following dosage forms) 1.1.2.1  Large volume liquids 1.5  Packaging 1.5.2  Secondary packaging2026-08-24—Public report detail and print PDF require a public database session. Open the report first; the print URL displays the currently selected report. EMA hosts national-authority reports. No source-stated modification date.eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187173The inspection resulted in a critical deficiency on inadequate cleaning validation as well as eight (8) major findings. These dealt with inadequate control of identification labels inside the manufacturing area, inadequate management of visual inspection activities, sterilized product passing through an area where un-sterilized bags were waiting to be autoclaved, inadequate container closure integrity testing and delayed action to correct this very long standing issue, process validation inadequacies, deficient complaint management, deficient management of aseptic process simulations as well as insufficient qualification of manufacturers and suppliers of critical starting materials and no reassurance that primary packaging materials for ophthalmic products were free from contamination. There were also 24 other deficiencies, in addition to the critical and major findings. All these observed deficiencies raise concerns that the approach to the manufacturing of sterile products is not adequately managing inherent risks pertaining to sterile processes and is not in line with applicable EU GMP requirements. As a result of this outcome, the Inspection Review Group (IRG) at the Malta Medicines Authority has met and decided that a Statement of Non-Compliance with the principles and guidelines of EU Good Manufacturing Practice is to be issued for the site.MT/003NCR/2026 - Aculife Healthcare Private Limitedeudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do?ctrl=searchGMPNCResultControlList&action=Drilldown&param=187173falseView row
416 rows × 26 columns
Get this sample as CSV or JSONFree. It opens in a workspace of your own, ready to export. Takes a minute.

About this dataset

Official GMP regulatory documents with source links, document references, source-stated dates and revisions, capture timestamps and document change tracking. Refreshed 19 November 2026 with 416 document records.

What you can use it for

Researchers can compare document records using content hashes and change fields. Regulatory teams can find documents by agency, date, document type or product area. Analysts can review warning-letter categories and document source links.

Coverage

FDA: 235 warning letters, 11 draft guidance documents and 11 final guidance documents. EMA: 6 GMP/GDP guidance documents. EudraLex: 38 Volume 4 references. Infarmed: 47 recall circulars, 10 GMP/GDP quality circulars and 8 restriction-lifted circulars. EudraGMDP: 50 public GMP non-compliance reports. Publication dates span August 2008 to 18 November 2026, including older current reference documents. Recent regulatory records use a rolling two-year discovery window; this is a scoped sample, not an exhaustive regulatory archive.

Delivery options

How Jsonify collected this data

Nobody wrote a scraper for this. Someone described the data they wanted, in a sentence, and Jason, Jsonify's AI data engineer, took it from there.

The illustration shows this pipeline’s saved steps and published data.

This pipeline refreshes on demand.

# dataIllustrated from this pipeline
  1. paulh

    @Jason I need this data: GMP guidance and warning letters from FDA, EMA, EudraLex and Infarmed, with document dates, source links and change-comparison fields. The published dataset contains 416 document records.

    Look at europa.eu, infarmed.pt and fda.gov.

  2. JasonApp

    Pipeline steps:

    • Sources
    • Discover
    • Organize
    • Extract documents
    • Changes

    Done. 416 documents published as v4:

    · Infarmed2026-11-19T18:05:28.740874+00:00

    Natural Essentials, Inc. · FDA2026-11-19T18:05:28.740874+00:00

Message #data

What Jason built

The pipeline itself, and the record of every version, repair and quality check since.

Data pipeline

Verified IndexPreviousSources416 documentsVerified Index — Optional verified official document index from an interrupted refresh. Omit for normal live discovery; use an exact captured dataset revision for recovery.
Input
Verified Index
Optional verified official document index from an interrupted refresh. Omit for normal live discovery; use an exact captured dataset revision for recovery.
Previous — Last published regulatory snapshot, used only for identity, first-seen dates and change comparisons.
Input
Previous
Last published regulatory snapshot, used only for identity, first-seen dates and change comparisons.
Sources — Prepare official regulatory sources and read the previous published snapshot for change comparisons.
Step
Sources
Prepare official regulatory sources and read the previous published snapshot for change comparisons.
Start
Discover — Discover current documents in FDA, EMA, European Commission and Infarmed official indexes.
Fan out
Discover
Discover current documents in FDA, EMA, European Commission and Infarmed official indexes.
Organize — Deduplicate document identities and interleave source families so bounded runs include balanced source coverage.
Step
Organize
Deduplicate document identities and interleave source families so bounded runs include balanced source coverage.
Extract documents — Retrieve documents or retain verified index metadata with explicit unavailable status when the document cannot be acquired.
Fan out
Extract documents
Retrieve documents or retain verified index metadata with explicit unavailable status when the document cannot be acquired.
Changes — Compare full document fingerprints with the last successfully published snapshot and retain original first-seen dates.
Step
Changes
Compare full document fingerprints with the last successfully published snapshot and retain original first-seen dates.
Main — Current official GMP regulatory documents with source traceability and changes since the last published snapshot.
Output
Main
Current official GMP regulatory documents with source traceability and changes since the last published snapshot.
End
Sources — europa.eu, fda.gov, infarmed.pt
Sources
europa.eu, fda.gov, infarmed.pt
  1. 01 · input

    Verified Index

    Optional verified official document index from an interrupted…

  2. 02 · input

    Previous

    Last published regulatory snapshot, used only for identity…

  3. 03 · sources

    Sources

    europa.eu, fda.gov, infarmed.pt

  4. 04

    Sources

    Prepare official regulatory sources and read the previous…

  5. 05 · fan out

    Discover

    Discover current documents in FDA, EMA, European Commission…

  6. 06

    Organize

    Deduplicate document identities and interleave source families…

  7. 07 · fan out

    Extract documents

    Retrieve documents or retain verified index metadata with…

  8. 08

    Changes

    Compare full document fingerprints with the last successfully…

  9. 09 · output

    Main

    Current official GMP regulatory documents with source…

    416 documents · v4

Ready to start?

Get this sample data, free

Jsonify collected this sample and publishes it under CC BY 4.0. Use it for anything, including commercially, as long as you credit Jsonify with a link to this page.

Credit it asData: Jsonify, CC BY 4.0, https://www.jsonify.com/datasets/fda-ema-and-infarmed-gmp-guidance-and-warning-letters-8099814fc1b9

The licence covers the dataset as Jsonify compiled it. It grants no rights in the source websites’ own content or trademarks.

Or buy the full dataset

The complete current dataset (416 documents), with its history, as a one-off export under a commercial licence.

  • Commercial use, no credit line. Yours to use in products, research and resale analysis.
  • Every row, every column. Not the sample: the whole dataset as of the day you buy it, plus past versions on request.
  • CSV, JSON or your warehouse. Delivered once, with the schema and source URLs.

Priced per dataset.

Or collect your own

Fork this pipeline into your own Jsonify account and run it yourself, or have us run a live feed for your team.

  • Commercial use, no credit line. Data you collect is yours under your Jsonify terms.
  • Kept current. It runs on your schedule, and Jason repairs it when a source changes.
  • Change alerts. Hear about new and changed rows in Slack, Teams or email.
  • Delivered where you work. Google Sheets, Excel, Snowflake, Postgres, S3 and more.
  • Your changes. Different sources, columns or coverage: tell Jason what to change.

100 free rows a month, then pay per row. See pricing

Frequently asked questions

Is this sample data free to use?
Yes. The sample on this page is published under CC BY 4.0. You can use it in your own work, products and research, including commercially, as long as you credit Jsonify.
How do I credit Jsonify?
Put this line wherever you show or publish the data, and say if you changed it: Data: Jsonify, CC BY 4.0, https://www.jsonify.com/datasets/fda-ema-and-infarmed-gmp-guidance-and-warning-letters-8099814fc1b9
Can I buy the full dataset?
Yes. The complete current dataset (every document), with its history on request, is available as a one-off export under a commercial licence: no credit line, yours to use in products and research. It is priced per dataset. Book a call for a quote.
How is that different from collecting my own?
The free sample is a slice of the data Jsonify collected, as of the date shown on this page. If you run the pipeline in your own Jsonify account, or have us run a live feed for you, the data you collect is yours to use under your Jsonify terms. It needs no credit line, and it stays current on your schedule.
What do Download and Customize do?
Both open a free Jsonify workspace of your own. Download puts this sample data in it, ready to export as CSV or JSON. Customize puts a copy of the pipeline in it, so you can change the sources, the documents it collects or the schedule.
Does collecting my own cost anything?
Your account includes free rows to start. Past that you pay for the rows you collect, as set out on the pricing page. Nothing is charged for the Download or Customize step itself.
What does a live feed for my team include?
Jsonify runs the pipeline for you on a schedule, sends change alerts, keeps the history, and adds the coverage you need. It is priced per team. Book a demo to scope it.
I run a site this data was read from. What can I do?
Jsonify reads public pages and credits each source. If something on this page should not be here, or you want your site left out of future runs, tell us and we will act on it. Report a problem or request removal.

Need something different?

Describe it. Get verified rows, kept current.

Migrate from your current tool

Share what you run on your current tool today. Jason, Jsonify’s AI data engineer, reads it and proposes the same pipelines on Jsonify, with checks and repairs built in.

Don’t include passwords or API keys. Exports, task configs and screenshots can be attached in Jsonify on the next step. Privacy

Connect your data assistant

Build datasets and work with your data in Claude, ChatGPT, Copilot or another assistant.

Connect in Claude

  1. Open the Jsonify connector: Open on Claude.ai ↗
  2. Select Connect and sign in to Jsonify.
  3. In a chat, enable Jsonify under + → Connectors and describe the data you need.
Advanced

Team or Enterprise account? Your workspace owner enables Jsonify once for everyone from Admin settings → Connectors. Jsonify is a community connector in the directory — some admins allow those by default, some review them first.

No directory? Add it by hand: Settings → Connectors → + Add custom connector, name it Jsonify, paste the server URL below, then Connect.

Server URLhttps://factory.jsonify.com/mcp

Official Claude custom-connector guide ↗

Then say: “build me a dataset of competitor product prices and availability, refreshed daily”. Full instructions per client on /connect.

What data do you need?

Describe it in a sentence or two. Jason proposes the sources, fields, checks and schedule before anything runs.

Try
100 rows a month free. No credit card.